Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02777073 · ClinicalTrials.gov registry record · NA
Effects of Single Doses of Liraglutide and Dapagliflozin on Ketogenesis in Type 1 Diabetes
A NA study, sponsored by University at Buffalo.
- Completed
- Registry status
- NA
- Development phase
- 43
- Enrollment target
NCT02777073 is a NA study that has completed, run by University at Buffalo. The registered enrollment target is 43 participants.
The verdict
NCT02777073, a NA study, has completed, sponsored by University at Buffalo.
- COMPLETED
- Registry status
- NA
- Development phase
- 43 participants
- Enrollment target
Study Summary
1. To compare levels of ketone bodies (beta-hydroxybutyrate and acetoacetate) in plasma and urine following a single dose treatment of either liraglutide 1.8mg, dapagliflozin 10mg or placebo in insulinopenic state. 2. To compare plasma levels of free fatty acid, glucagon, hs-CRP, Ll-6 and IL-1 before and after administration of liraglutide/placebo.
Interventions
- DRUG Placebo
- DRUG Dapagliflozin 10mg Tab
- DRUG Victoza
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2016-03-01 |
| Est. Completion | 2016-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02777073
The ClinicalTrials.gov registry entry for NCT02777073 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University at Buffalo, which has 67 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02777073 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02777073 about?
NCT02777073 is a clinical study titled "Effects of Single Doses of Liraglutide and Dapagliflozin on Ketogenesis in Type 1 Diabetes". 1. To compare levels of ketone bodies (beta-hydroxybutyrate and acetoacetate) in plasma and urine following a single dose treatment of either liraglutide 1.8mg, dapagliflozin 10mg or placebo in insulinopenic state. 2. To compare plasma levels of free fatty acid, glucagon, hs-CRP, Ll-6 and IL-1 befor...
What is the current status of trial NCT02777073?
This trial is currently completed. It is a NA study. The enrollment target is 43 participants. The study started on 2016-03-01. Estimated completion is 2016-12-31.
What interventions are being tested in trial NCT02777073?
The interventions under investigation include: Placebo (DRUG), Dapagliflozin 10mg Tab (DRUG), Victoza (DRUG).
Who is sponsoring clinical trial NCT02777073?
This trial is sponsored by University at Buffalo, which has 67 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.